Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476781 | 0.84 | HRH3 (0.43) | EBPHRH3PKMEGLN1SRD5A1 | |
| SCHEMBL2473880 | 0.81 | MEN1 (0.42) | HRH3PKMEGLN1ALDH1A1SRD5A1 | |
| SCHEMBL2479488 | 0.79 | LMNA (0.42) | EBPHRH3PKMEGLN1LMNA | |
| SCHEMBL2475798 | 0.78 | HRH3 (0.53) | HRH3 | |
| SCHEMBL2475353 | 0.77 | HRH3 (0.39) | HRH3EGLN1ALDH1A1 | |
| SCHEMBL2476740 | 0.74 | HRH3 (0.56) | EBPHRH3EGLN1 | |
| SCHEMBL2473890 | 0.74 | MEN1 (0.40) | HRH3EGLN1SRD5A1 | |
| SCHEMBL17102319 | 0.73 | NOTUM (0.54) | PDE3BPDE3ANOTUMKDM4EALDH1A1 | |
| SCHEMBL29623590 | 0.73 | NOTUM (0.54) | PDE3BPDE3ANOTUMKDM4EALDH1A1 | |
| SCHEMBL2478869 | 0.72 | HRH3 (0.59) | EBPHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373659-B1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-07-30 | — | — | EP | disclosed |
| EP-2373659-B1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-07-30 | — | — | EP | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383814-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-20 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-8217052-B2 | Substituted tetrahydropyran spiro pyrrolidinone and piperidinone, preparation and therapeutic use thereof | SANOFI (FR) | 2012-07-10 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-13 | — | — | US | disclosed |
| EP-2373659-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065798-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251225-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | EBP 2737/4885PDE3B 4312/4885PDE3A 3519/4885 |
| US-20120238757-A1 | SUBSTITUTED TETRAHYDROPYRAN SPIRO PYRROLIDINONE AND PIPERIDINONE, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | EBP 2737/4885PDE3B 4312/4885PDE3A 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.